ENSYSCE BIOSCIENCES, INC.: 10-Q filed 2023-11-09

Name: ENSYSCE BIOSCIENCES, INC.: 10-Q filed 2023-11-09
Creator: ENSYSCE BIOSCIENCES, INC.

What ENSYSCE BIOSCIENCES, INC. reported in its quarterly report filed 2023-11-09 (fiscal Q3 2023): 33 published measures, 95 facts as tagged in accession 0001493152-23-040091.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-11-09
Fiscal period: fiscal Q3 2023
Accession: 0001493152-23-040091 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ENSYSCE BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	3,218,686	USD
At 2022-12-31	5,885,052	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-09-30	2,061,011	USD
At 2022-12-31	9,914,704	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2023-09-30	1,485,119	USD
At 2022-12-31	-3,714,444	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-09-30	1,464,381	USD
At 2022-12-31	3,147,702	USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-8,978,107	USD	273
2022-01-01 to 2022-09-30	-14,591,819	USD	273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	435,380	USD	92
2023-01-01 to 2023-09-30	1,715,488	USD	273
2022-07-01 to 2022-09-30	279,351	USD	92
2022-01-01 to 2022-09-30	1,089,920	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	7,294,786	USD	273
2022-01-01 to 2022-09-30	6,825,664	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	4,500	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-118,052,779	USD
At 2022-12-31	-110,931,063	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	3,085,873	shares	92
2023-01-01 to 2023-09-30	2,145,505	shares	273
2022-07-01 to 2022-09-30	160,719	shares	92
2022-01-01 to 2022-09-30	138,849	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	3,085,873	shares	92
2023-01-01 to 2023-09-30	2,145,505	shares	273
2022-07-01 to 2022-09-30	160,719	shares	92
2022-01-01 to 2022-09-30	138,849	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-0.87	USD/shares	92
2023-01-01 to 2023-09-30	-3.32	USD/shares	273
2022-07-01 to 2022-09-30	-61.58	USD/shares	92
2022-01-01 to 2022-09-30	-140.9	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-0.87	USD/shares	92
2023-01-01 to 2023-09-30	-3.32	USD/shares	273
2022-07-01 to 2022-09-30	-61.58	USD/shares	92
2022-01-01 to 2022-09-30	-140.9	USD/shares	273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	250,224	USD	273
2022-01-01 to 2022-09-30	855,160	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-2,707,314	USD	92
2023-01-01 to 2023-09-30	-7,562,502	USD	273
2022-07-01 to 2022-09-30	-6,163,325	USD	92
2022-01-01 to 2022-09-30	-18,021,309	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-09-30	2,757,803	USD
At 2022-12-31	5,299,169	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	7,649	USD	92
2023-01-01 to 2023-09-30	9,146	USD	273
2022-07-01 to 2022-09-30	4,859	USD	92
2022-01-01 to 2022-09-30	57,662	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	2,030,538	USD
At 2022-12-31	9,464,210	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-09-30	916,416	USD
At 2022-12-31	2,943,791	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	3,142,694	USD	92
2023-01-01 to 2023-09-30	9,277,990	USD	273
2022-07-01 to 2022-09-30	6,442,676	USD	92
2022-01-01 to 2022-09-30	19,111,229	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	1,914,970	USD	92
2023-01-01 to 2023-09-30	5,354,713	USD	273
2022-07-01 to 2022-09-30	4,756,096	USD	92
2022-01-01 to 2022-09-30	13,393,948	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	2,864,004	shares
At 2022-12-31	534,490	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-09-30	119,537,611	USD
At 2022-12-31	107,216,566	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2023-09-30	1,157,675	USD
At 2023-06-30	3,792,807	USD
At 2022-12-31	-4,029,652	USD
At 2022-09-30	-6,421,932	USD
At 2022-06-30	-797,578	USD
At 2021-12-31	-8,158,058	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2023-09-30	460,883	USD
At 2022-12-31	585,883	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-2,690,806	USD	92
2023-01-01 to 2023-09-30	-7,121,914	USD	273
2022-07-01 to 2022-09-30	-9,855,565	USD	92
2022-01-01 to 2022-09-30	-18,729,609	USD	273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-2,689,571	USD	92
2023-01-01 to 2023-09-30	-7,121,716	USD	273
2022-07-01 to 2022-09-30	-9,897,612	USD	92
2022-01-01 to 2022-09-30	-19,563,588	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	1,227,724	USD	92
2023-01-01 to 2023-09-30	3,923,277	USD	273
2022-07-01 to 2022-09-30	1,686,580	USD	92
2022-01-01 to 2022-09-30	5,717,281	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	6,934	USD	92
2023-01-01 to 2023-09-30	23,382	USD	273
2022-07-01 to 2022-09-30	8,679	USD	92
2022-01-01 to 2022-09-30	19,494	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	16,508	USD	92
2023-01-01 to 2023-09-30	440,588	USD	273
2022-07-01 to 2022-09-30	-3,692,240	USD	92
2022-01-01 to 2022-09-30	-708,300	USD	273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	1,600	USD	273

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	2,732	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-2,027,375	USD	273
2022-01-01 to 2022-09-30	984,410	USD	273

Inspect the source

Entity: ENSYSCE BIOSCIENCES, INC. / CIK 0001716947
Captured: 2026-09-21T17:24:39.335Z
SEC response SHA-256: 28573a09f81da1511239531464c03b2552a3554a684a233653f365b194b6ca0b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001716947.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))